These findings demonstrate that higher plasma levels of BCKA and hepatic expression of BCKDK are features of human NAFLD/NASH and identify SREBP1 as a transcriptional regulator of BCKDK. The gene discussed is SREBF1; the disease is metabolic dysfunction-associated steatotic liver disease.